277
Participants
Start Date
March 31, 2010
Primary Completion Date
July 31, 2014
Study Completion Date
July 31, 2014
Tivozanib
Tivozanib capsules, administered orally, on a dosing schedule of 3 weeks of treatment (beginning on Day 1) followed by 1 week off treatment. One cycle was defined as 4 weeks of treatment.
Sorafenib
Sorafenib tablets, 400 mg twice daily, administered orally for 4 weeks (1 cycle = 4 weeks). One cycle was defined as 4 weeks of treatment. Cycles were repeated every 4 weeks.
Site 404, Sofia
Site 400, Sofia
Site 403, Plovdiv
Site 402, Veliko Tarnovo
Site 401, Varna
Site 480, Belgrade
Site 481, Belgrade
Site 482, Belgrade
Site 491, Chernihiv
Site 483, Niš
Site 484, Kamenitz
Site 161, Pavia
Site 184, Orlando
Site 133, Saint-Herblain
Site 498, Dniproperovsk
Site 492, Dniproperovsk
Site 160, Arezzo
Site 182, Minneapolis
Site 494, Kharkiv
Site 495, Zaporizhia
Site 187, Dallas
Site 490, Ivano-Frankivsk
Site 493, Donetsk
Site 496, Donetsk
Site 497, Uzhhorod
Site 185, Los Angeles
Site 454, Moscow
Site 154, Delhi
Site 453, Moscow
Site 458, Moscow
Site 460, Moscow
Site 461, Moscow
Site 462, Moscow
Site 464, Yaroslavl
Site 466, Saint Petersburg
Site 465, Saint Petersburg
Site 158, Lucknow
Site 456, Obninsk
Site 442, Timișoara
Site 191, Jaipur
Site 457, Rostov-on-Don
Site 463, Pyatigorsk
Site 156, Ahmedabad
Site 153, Pune
Site 452, Kazan'
Site 151, Nashik
Site 459, Ufa
Site 451, Chelyabinsk
Site 444, Brasov
Site 450, Nizhny Novgorod
Site 455, Yekaterinburg
Site 152, Vellore
Site 467, Omsk
Site 150, Kolkata
Site 123, Temuco
Site 122, Santiago
Site 186, New York
Site 110, Montreal
Site 411, Prague
Site 423, Budapest
Site 421, Kaposvár
Site 422, Pécs
Site 162, Roma
Site 432, Bialystok
Site 434, Bydgoszcz
Site 431, Gdansk
Site 435, Olsztyn
Site 433, Poznan
Site 430, Warsaw
Site 436, Warsaw
Site 441, Bucharest
Site 440, Bucharest
Site 443, Bucharest
Site 170, Cambridge
Site 172, Leicester
Lead Sponsor
AVEO Pharmaceuticals, Inc.
INDUSTRY